Description
ALECENSA is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
How to use:
- 600 mg orally twice daily. Administer ALECENSA with food.
Caution & Warnings:
- Hepatotoxicity
- Interstitial Lung Disease (ILD)/Pneumonitis
- Renal Impairment
- Bradycardia
- Severe Myalgia and Creatine Phosphokinase (CPK) Elevation
- Hemolytic Anemia
- Embryo-Fetal Toxicity
Side Effects:
- fatigue, constipation, edema, myalgia, and anemia.
Ingredients:
- Alectinib 150Mg.
Reviews
There are no reviews yet.